Niagen Bioscience, Inc. — Director's Dealing 2017

Jul 5, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2017-06-20

Reporting Person: GUSTAFSON KURT A (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-20	Stock Options (right to buy)	$3.59	A	20000	Acquired	2027-06-20	Common Stock (20000)	Direct

Footnotes

F1: Options vest 100% on June 20, 2018.